{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:32:49Z","timestamp":1786689169780,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03753-7","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:20:37Z","timestamp":1786688437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Costs of Comorbidities and Complications Associated with Type\u00a02 Diabetes: A Retrospective, Cohort Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0915-3982","authenticated-orcid":false,"given":"Kendra A.","family":"Terrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4961-2027","authenticated-orcid":false,"given":"Maureen J.","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-6813","authenticated-orcid":false,"given":"William J.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7134-3519","authenticated-orcid":false,"given":"Jim S.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5953-5929","authenticated-orcid":false,"given":"Kristina S.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"3753_CR1","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. Published 29 Nov 2023. https:\/\/stacks.cdc.gov\/view\/cdc\/148231. Accessed 22 Dec 2025."},{"key":"3753_CR2","unstructured":"Centers for Disease Control and Prevention. Diabetes in the US, a US report card. Updated 11 Feb 2026. https:\/\/www.cdc.gov\/diabetes\/images\/library\/socialmedia\/diabetesintheus_print.pdf. Accessed 17 July 2026."},{"issue":"1","key":"3753_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12916-019-1373-y","volume":"17","author":"M Nowakowska","year":"2019","unstructured":"Nowakowska M, Zghebi SS, Ashcroft DM, et al. The comorbidity burden of type\u00a02 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17(1):145.","journal-title":"BMC Med"},{"issue":"5","key":"3753_CR4","first-page":"421","volume":"19","author":"R Li","year":"2013","unstructured":"Li R, Bilik D, Brown MB, et al. Medical costs associated with type\u00a02 diabetes complications and comorbidities. Am J Manag Care. 2013;19(5):421\u201330.","journal-title":"Am J Manag Care"},{"issue":"3","key":"3753_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.amepre.2013.04.017","volume":"45","author":"X Zhuo","year":"2013","unstructured":"Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type\u00a02 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253\u201361.","journal-title":"Am J Prev Med"},{"issue":"4","key":"3753_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jdiacomp.2014.12.009","volume":"29","author":"SD Candrilli","year":"2015","unstructured":"Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type\u00a02 diabetes-related comorbidities. J Diabetes Complications. 2015;29(4):529\u201333.","journal-title":"J Diabetes Complications"},{"issue":"11","key":"3753_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.2337\/dc21-2151","volume":"45","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang P, Shao H, Andes LJ, Imperatore G. Medical costs associated with diabetes complications in Medicare beneficiaries aged 65\u00a0years or older with type\u00a02 diabetes. Diabetes Care. 2022;45(11):2570\u20136.","journal-title":"Diabetes Care"},{"issue":"12","key":"3753_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S2213-8587(19)30081-6","volume":"7","author":"D Selvarajah","year":"2019","unstructured":"Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019;7(12):938\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3753_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type\u00a02 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"3753_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17010207","volume":"17","author":"M Mirabelli","year":"2019","unstructured":"Mirabelli M, Chiefari E, Caroleo P, et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type\u00a02 diabetes. Int J Environ Res Public Health. 2019;17(1):207.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"3753_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","volume":"12","author":"YK Cho","year":"2023","unstructured":"Cho YK, Lee YL, Jung CH. The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler. 2023;12(3):213\u201322.","journal-title":"J Lipid Atheroscler"},{"issue":"1","key":"3753_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","volume":"32","author":"N Kr\u00fcger","year":"2026","unstructured":"Kr\u00fcger N, Schneeweiss S, Desai RJ, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type\u00a02 diabetes in clinical practice. Nat Med. 2026;32(1):342\u201352.","journal-title":"Nat Med"},{"issue":"10","key":"3753_CR13","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatment for obesity in adults. Nat Med. 2025;31(10):3317\u201329.","journal-title":"Nat Med"},{"issue":"1","key":"3753_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","volume":"2","author":"I Caruso","year":"2024","unstructured":"Caruso I, Cignarelli A, Sorice GP, Perrini S, Giorgino F. Incretin-based therapies for the treatment of obesity-related diseases. NPJ Metab Health Dis. 2024;2(1):31.","journal-title":"NPJ Metab Health Dis"},{"issue":"1","key":"3753_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/13696998.2022.2035132","volume":"25","author":"RF Pollock","year":"2022","unstructured":"Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME type\u00a02 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type\u00a02 diabetes mellitus. J Med Econ. 2022;25(1):393\u2013402.","journal-title":"J Med Econ"},{"key":"3753_CR16","unstructured":"Eli Lilly and Company. A study of retatrutide (LY3437943) in participants who have obesity or overweight and chronic low back pain (TRIUMPH-7). Clinicaltrials.gov Identifier NCT07035093. Updated 10 Feb 2026. https:\/\/clinicaltrials.gov\/study\/NCT07035093?intr=retatrutide&rank=2. Accessed 27 Feb 2026."},{"key":"3753_CR17","unstructured":"Eli Lilly and Company. A study of retatrutide (LY3437943) on renal function in participants with overweight or obesity and chronic kidney disease with or without type\u00a02 diabetes. Clinicaltrials.gov Identifier NCT05936151. Updated 25 Nov 2025. https:\/\/clinicaltrials.gov\/study\/NCT05936151. Accessed 27 Feb 2026."},{"key":"3753_CR18","unstructured":"Eli Lilly and Company. A study of retatrutide (LY3437943) once weekly in participants who have obesity or overweight and osteoarthritis of the knee (TRIUMPH-4). Clinicaltrials.gov Identifier NCT05931367. Updated 21 Jan 2026. https:\/\/clinicaltrials.gov\/study\/NCT05931367?intr=retatrutide&page=2&rank=14. Accessed 27 Feb 2026."},{"key":"3753_CR19","unstructured":"Eli Lilly and Company. A master protocol of multiple agents in adults with metabolic dysfunction-associated steatotic liver disease (SYNERGY-Outcomes). Clinicaltrials.gov Identifier NCT07165028. Updated 10 Feb 2026. https:\/\/clinicaltrials.gov\/study\/NCT07165028?intr=retatrutide&page=2&rank=16. Accessed 27 Feb 2026."},{"key":"3753_CR20","unstructured":"Eli Lilly and Company. A study of retatrutide (LY3437943) in participants with type\u00a02 diabetes mellitus who have obesity or overweight (TRIUMPH-2). Clinicaltrials.gov Identifier NCT05929079. Updated 18 Apr 2025. https:\/\/clinicaltrials.gov\/study\/NCT05929079?intr=retatrutide&page=2&rank=13. Accessed 27 Feb 2026."},{"issue":"5","key":"3753_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa0806375","volume":"360","author":"LL Subak","year":"2009","unstructured":"Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"3753_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1164\/rccm.201912-2511OC","volume":"203","author":"ST Kuna","year":"2021","unstructured":"Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the Sleep AHEAD study. Am J Respir Crit Care Med. 2021;203(2):221\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3753_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-025-01579-1","volume":"25","author":"MW Takawy","year":"2025","unstructured":"Takawy MW, Abdelmalek MF. Impact of weight loss on metabolic dysfunction-associated steatohepatitis and hepatic fibrosis. Curr Diab Rep. 2025;25(1):23.","journal-title":"Curr Diab Rep"},{"issue":"8","key":"3753_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13230","volume":"22","author":"S Panunzi","year":"2021","unstructured":"Panunzi S, Maltese S, De Gaetano A, Capristo E, Bornstein SF, Mingrone G. Comparative efficacy of different weight loss treatments on knee osteoarthritis: a network meta-analysis. Obes Rev. 2021;22(8):e13230.","journal-title":"Obes Rev"},{"issue":"9","key":"3753_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238843","volume":"15","author":"G Li","year":"2019","unstructured":"Li G, Zhang L, DiBerenardo A, et al. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistent depression in commercially insured US patients. PLoS ONE. 2019;15(9):e0238843.","journal-title":"PLoS ONE"},{"issue":"3","key":"3753_CR26","first-page":"311","volume":"26","author":"VN Joish","year":"2020","unstructured":"Joish VN, Zhou FL, Preblick R, et al. Estimation of annual health care costs for adults with type\u00a01 diabetes in the United States. J Manag Care Spec Pharm. 2020;26(3):311\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"3753_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","volume":"22","author":"M Sittimart","year":"2024","unstructured":"Sittimart M, Rattanavipapong W, Mirelman AJ, et al. An overview of the perspectives used in health economic evaluations. Cost Eff Resour Alloc. 2024;22:41.","journal-title":"Cost Eff Resour Alloc"},{"key":"3753_CR28","unstructured":"United States Bureau of Labor Statistics. Consumer price index for all urban consumers (CPI-U) \u2013 Series id CUUR0000SAM, CUUS0000SAM. https:\/\/www.bls.gov\/cpi\/. Accessed 22 Dec 2025."},{"issue":"4","key":"3753_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1258\/1355819042250249","volume":"9","author":"J Barber","year":"2004","unstructured":"Barber J, Thompson S. Multiple regression of costs data: use of generalized linear models. J Health Serv Res Policy. 2004;9(4):197\u2013204.","journal-title":"J Health Serv Res Policy"},{"issue":"1","key":"3753_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jval.2013.10.004","volume":"17","author":"D Coughlan","year":"2014","unstructured":"Coughlan D, Yeh ST, O\u2019Neil C, Frick KD. Evaluating direct medical expenditures estimation methods of adults using the medical expenditure panel survey: an example focusing on head and neck cancer. Value Health. 2014;17(1):90\u20137.","journal-title":"Value Health"},{"key":"3753_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13561-015-0045-7","volume":"5","author":"AS Malehi","year":"2015","unstructured":"Malehi AS, Pourmotahari F, Angali KA. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Econ Rev. 2015;5:11.","journal-title":"Health Econ Rev"},{"issue":"3","key":"3753_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40273-023-01319-x","volume":"42","author":"J Zhou","year":"2023","unstructured":"Zhou J, Williams C, Keng MJ, Wu R, Mihaylova B. Estimating costs associated with disease model states using generalized linear models: a tutorial. Pharmacoeconomics. 2023;42(3):261\u201373.","journal-title":"Pharmacoeconomics"},{"key":"3753_CR33","unstructured":"Li Z, Mehendra G. Using \u201crecycled predictions\u201d for computing marginal effects. SAS Global Forum 2010, Paper 272\u20132010. https:\/\/support.sas.com\/resources\/papers\/proceedings10\/272-2010.pdf. Accessed 26 Feb 2026."},{"issue":"2","key":"3753_CR34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.0006-341X.1999.00652.x","volume":"55","author":"B Graubard","year":"1999","unstructured":"Graubard B, Korn EL. Predictive margins with survey data. Biometrics. 1999;55(2):652\u20139.","journal-title":"Biometrics"},{"key":"3753_CR35","unstructured":"Blakeslee L, Calan Z, Meyer JA, Rabe MA, Roberts AW. Age and sex composition: 2020. Report Number C2020BR-06. Published May\u00a02023. https:\/\/www2.census.gov\/library\/publications\/decennial\/2020\/census-briefs\/c2020br-06.pdf. Accessed 27 Feb 2026."},{"issue":"1","key":"3753_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0978-2","volume":"15","author":"S Cortaredona","year":"2017","unstructured":"Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 2017;15(1):216.","journal-title":"BMC Med"},{"issue":"12","key":"3753_CR37","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-020-05277-3","volume":"63","author":"E Anderson","year":"2020","unstructured":"Anderson E, Persson S, Hall\u00e9n N, et al. Costs of diabetes complications: hospital-based care and absence from work for 392,000 people with type\u00a02 diabetes and matched control participants in Sweden. Diabetologia. 2020;63(12):2582\u201394.","journal-title":"Diabetologia"},{"issue":"1","key":"3753_CR38","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc25-S006","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes\u2013\u20132025. Diabetes Care. 2025;48(1):S128\u201345.","journal-title":"Diabetes Care"},{"key":"3753_CR39","unstructured":"Centers for Disease Control and Prevention. Adults BMI categories. Published 19 March 2024. https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html. Accessed 27 Feb 2026."},{"key":"3753_CR40","unstructured":"National Committee for Quality Assurance. Glycemic status assessment for patients with diabetes (GSD). Published 2026. https:\/\/www.ncqa.org\/report-cards\/health-plans\/state-of-health-care-quality-report\/glycemic-status-assessment-for-patients-with-diabetes-gsd\/. Accessed 12 Feb 2026."},{"key":"3753_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CEOR.S247498","volume":"12","author":"J Visaria","year":"2020","unstructured":"Visaria J, Iyer NN, Raval AD, et al. Healthcare costs of diabetes and microvascular and macrovascular disease in individuals with incident type\u00a02 diabetes mellitus: a ten-year longitudinal study. Clinicoecon Outcomes Res. 2020;12:423\u201334.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"3753_CR42","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s13300-018-0477-2","volume":"9","author":"P Lin","year":"2018","unstructured":"Lin P, Pope E, Zhou FL. Comorbidity type and health care costs in type\u00a02 diabetes: a retrospective claims database analysis. Diabetes Ther. 2018;9(5):1907\u201318.","journal-title":"Diabetes Ther"},{"issue":"8","key":"3753_CR43","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2337\/dc24-2746","volume":"48","author":"D Zhang","year":"2025","unstructured":"Zhang D, Gencerliller N, Mukhopadhyay A, et al. Association of patient cost sharing with adherence to GLP-1RA and adverse health outcomes. Diabetes Care. 2025;48(8):1329-36.43.","journal-title":"Diabetes Care"},{"issue":"2","key":"3753_CR44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40200-025-01770-x","volume":"24","author":"F Ameer","year":"2025","unstructured":"Ameer F, Villacres NY, Bustos D, et al. Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review. J Diabetes Metab Disord. 2025;24(2):253.","journal-title":"J Diabetes Metab Disord"},{"issue":"4","key":"3753_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2337\/dc19-0573","volume":"43","author":"M Mata-Cases","year":"2020","unstructured":"Mata-Cases M, Rodr\u00edguez-S\u00e1nchez B, Mauricio D, et al. The association between poor glycemic control and health care costs in people with diabetes: a population-based study. Diabetes Care. 2020;43(4):751\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"3753_CR46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1017\/S026646231800017X","volume":"34","author":"RS Henriques","year":"2018","unstructured":"Henriques RS, Steimbach LM, Baptista DR, et al. Direct costs of type\u00a02 diabetes: a Brazilian cost-of-illness study. Int J Technol Assess Health Care. 2018;34(2):180\u20138.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"3753_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s13300-022-01212-4","volume":"13","author":"KS Boye","year":"2022","unstructured":"Boye KS, Lage MJ, Thieu VT. The association between HbA1c and 1-year diabetes-related medical costs: a retrospective claims database analysis. Diabetes Ther. 2022;13(2):367\u201377.","journal-title":"Diabetes Ther"},{"issue":"9131","key":"3753_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type\u00a02 diabetes (UKPDS 33). Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"issue":"5","key":"3753_CR49","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1007\/s12325-022-02106-4","volume":"39","author":"KS Boye","year":"2022","unstructured":"Boye KS, Thieu VT, Lage MJ, Miller H, Paczkowski R. The association between sustained HbA1c control and long-term complications among individuals with type\u00a02 diabetes: a retrospective study. Adv Ther. 2022;39(5):2208\u201321.","journal-title":"Adv Ther"},{"issue":"1","key":"3753_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/dme.13533","volume":"35","author":"SA Mostafa","year":"2018","unstructured":"Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA. Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with type\u00a02 diabetes and cardiovascular disease. Diabetes Med. 2018;35(1):72\u20137.","journal-title":"Diabetes Med"},{"key":"3753_CR51","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.5888\/pcd22.240539","volume":"22","author":"KB Watson","year":"2025","unstructured":"Watson KB, Wiltz JL, Nhim K, Kaurmann RB, Thomas CW, Greenlund KJ. Trends in multiple chronic conditions among US adults, by life stage, behavioral risk factor surveillance system, 2013\u20132023. Prev Chronic Dis. 2025;22:E15.","journal-title":"Prev Chronic Dis"},{"key":"3753_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40985-016-0043-2","volume":"37","author":"E Velasco-Mondragon","year":"2016","unstructured":"Velasco-Mondragon E, Jimenez A, Palladino-Davis AG, Davis D, Escamilla-Cejudo JA. Hispanic health in the USA: a scoping review of the literature. Public Health Rev. 2016;37:31.","journal-title":"Public Health Rev"},{"key":"3753_CR53","volume-title":"StatPearls [Internet]","author":"Y Lim","year":"2025","unstructured":"Lim Y, Haq N, Boster J. Obesity and comorbid conditions. In: StatPearls [Internet]. Treasure Island: StatPearls; 2025."},{"issue":"4","key":"3753_CR54","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13300-023-01384-7","volume":"14","author":"KS Boye","year":"2023","unstructured":"Boye KS, Ford JH, Thieu VT, Lage MJ, Terrell KA. The association between obesity and the 5-year prevalence of morbidity and mortality among adults with type\u00a02 diabetes. Diabetes Ther. 2023;14(4):709\u201321.","journal-title":"Diabetes Ther"},{"issue":"2","key":"3753_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/oby.23639","volume":"31","author":"Z Li","year":"2023","unstructured":"Li Z, Daniel S, Fujioka K, Umashanker D. Obesity among Asian American people in the United States: a review. Obesity. 2023;31(2):316\u201328.","journal-title":"Obesity"},{"issue":"3","key":"3753_CR56","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ecl.2021.05.012","volume":"50","author":"M Cicek","year":"2021","unstructured":"Cicek M, Buckley J, Pearson-Stuttard J, Gregg EW. Characterizing multimorbidity from type\u00a02 diabetes: insights from clustering approaches. Endocrinol Metab Clin North Am. 2021;50(3):531\u201358.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"3753_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107979","volume":"26","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, He P, Yao H, et al. A network-based study reveals multimorbidity patterns in people with type\u00a02 diabetes. iScience. 2023;26(10):107979.","journal-title":"iScience"},{"issue":"Suppl 1","key":"3753_CR58","first-page":"S5","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin. 2004;20(Suppl 1):S5-26.","journal-title":"Curr Med Res Opin"},{"key":"3753_CR59","unstructured":"United States Census Bureau. Uninsured rates down in 194 counties, up in 85 counties. Published 31 July 2025. https:\/\/www.census.gov\/newsroom\/press-releases\/2025\/small-area-health-insurance-estimates.html. Accessed 02 May\u00a02026."},{"key":"3753_CR60","unstructured":"Centers for Medicare and Medicaid Services. Medicare and Medicaid by the numbers. Published July 2025. https:\/\/www.cms.gov\/files\/document\/medicare-and-medicaid-numbers.pdf. Accessed 02 May, 2026."},{"key":"3753_CR61","unstructured":"United States Census Bureau. U.S. population grows at fastest pace in more than two decades. Published 19 Dec 2024. https:\/\/www.census.gov\/library\/stories\/2024\/12\/population-estimates.html. Accessed 02 May\u00a02026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03753-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03753-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:20:40Z","timestamp":1786688440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03753-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":61,"alternative-id":["3753"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03753-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kristina S Boye, Jim S Paik, and Kendra A Terrell completed this research as employees and shareholders at Eli Lilly and Company. Maureen J Lage was compensated by Eli Lilly and Company for her work on this research. William J Valentine is employed by a company that has been compensated by Eli Lilly and Company for prior research.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were compliant with the Health Insurance Portability and Accountability Act (HIPAA). Given the use of retrospective, de-identified data, no Institutional Review Board approval was required. Permission was received from Optum to utilize the data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}